Efficacy and safety of ibrutinib in central nervous system lymphoma: A systematic review and meta-analysis

<h3>Background</h3><p dir="ltr"><u>Primary central nervous system lymphoma</u> (CNSL) is a rare, aggressive non-Hodgkin lymphoma confined to the CNS. Although radiation and chemotherapy, particularly high-dose <u>methotrexate</u> (HD-MTX), are effe...

Full description

Saved in:

Bibliographic Details
Main Author:	Jaber H. Jaradat (21632849) (author)
Other Authors:	Ibraheem M. Alkhawaldeh (17430888) (author), Yousef Al-Bojoq (22282816) (author), Monther N. Ramadan (22282819) (author), Mohammad T. Abuawwad (17632242) (author), Yasmeen Jamal Alabdallat (19920491) (author), Abdulqadir J. Nashwan (11659453) (author)
Published:	2024
Subjects:	Biomedical and clinical sciences Cardiovascular medicine and haematology Immunology Oncology and carcinogenesis Pharmacology and pharmaceutical sciences Ibrutinib BTK Bruton tyrosine kinase inhibitor CNSL Central nervous system lymphoma Lymphoma
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Efficacy and safety of ibrutinib in central nervous system lymphoma: A systematic review and meta-analysis

Similar Items